EA201591355A1 - АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА - Google Patents

АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА

Info

Publication number
EA201591355A1
EA201591355A1 EA201591355A EA201591355A EA201591355A1 EA 201591355 A1 EA201591355 A1 EA 201591355A1 EA 201591355 A EA201591355 A EA 201591355A EA 201591355 A EA201591355 A EA 201591355A EA 201591355 A1 EA201591355 A1 EA 201591355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding proteins
fms
antigen
person
tumor
Prior art date
Application number
EA201591355A
Other languages
English (en)
Russian (ru)
Inventor
Кеннет Аллан Брейзел
Стивен Фостер
Дуглас Пэт Серретти
Джилин Сан
Джеймс Ф. Смозерс
Кристофер Мелин
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201591355A1 publication Critical patent/EA201591355A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
EA201591355A 2007-08-21 2008-08-19 АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА EA201591355A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95714807P 2007-08-21 2007-08-21
US8458808P 2008-07-29 2008-07-29

Publications (1)

Publication Number Publication Date
EA201591355A1 true EA201591355A1 (ru) 2016-04-29

Family

ID=40019258

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000357A EA023555B1 (ru) 2007-08-21 2008-08-19 АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
EA201591355A EA201591355A1 (ru) 2007-08-21 2008-08-19 АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201000357A EA023555B1 (ru) 2007-08-21 2008-08-19 АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА

Country Status (30)

Country Link
US (4) US8182813B2 (enExample)
EP (4) EP3330292A1 (enExample)
JP (3) JP5718640B2 (enExample)
KR (1) KR101770429B1 (enExample)
CN (1) CN101802008B (enExample)
AR (1) AR068347A1 (enExample)
AU (1) AU2008288974B2 (enExample)
BR (1) BRPI0815368A2 (enExample)
CA (1) CA2696761C (enExample)
CL (1) CL2008002444A1 (enExample)
CR (1) CR11282A (enExample)
CY (1) CY1119755T1 (enExample)
DK (1) DK2188313T3 (enExample)
EA (2) EA023555B1 (enExample)
ES (1) ES2650224T3 (enExample)
HR (1) HRP20171741T1 (enExample)
HU (1) HUE037265T2 (enExample)
LT (1) LT2188313T (enExample)
MX (1) MX2010001918A (enExample)
NO (1) NO2188313T3 (enExample)
NZ (1) NZ583282A (enExample)
PE (1) PE20091004A1 (enExample)
PL (1) PL2188313T3 (enExample)
PT (1) PT2188313T (enExample)
RS (1) RS56743B1 (enExample)
SG (1) SG10201500328QA (enExample)
SI (1) SI2188313T1 (enExample)
TW (1) TWI595005B (enExample)
WO (1) WO2009026303A1 (enExample)
ZA (1) ZA201001541B (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
MX2010009894A (es) 2008-03-14 2011-02-22 Transgene Sa Anticuerpo contra csf-1r.
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
IT1394281B1 (it) * 2009-01-19 2012-06-06 Zardi Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.
WO2011002494A1 (en) * 2009-07-01 2011-01-06 University Of Tenessee Research Foundation Use of immunoglobulin heavy and light chains or fragments therof to bind to aggregated amyloidogenic proteins
PL2949670T3 (pl) 2009-12-10 2019-07-31 F. Hoffmann-La Roche Ag Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
US9169323B2 (en) * 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9221910B2 (en) * 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AU2011248083B2 (en) * 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
WO2012051111A2 (en) 2010-10-13 2012-04-19 Janssen Biotech, Inc. Human oncostatin m antibodies and methods of use
PT2673373T (pt) 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
CN102719404B (zh) * 2011-03-30 2015-02-18 中国人民解放军军事医学科学院毒物药物研究所 用于筛选c-Fms激酶抑制剂的细胞模型及筛选方法
EP3865507A1 (en) 2011-05-17 2021-08-18 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
WO2013011021A1 (en) * 2011-07-18 2013-01-24 The University Of Melbourne Use of c-fms antagonists
JP6005751B2 (ja) 2011-10-21 2016-10-12 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マクロファージの活性化の調節
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
JP6669672B2 (ja) * 2014-06-10 2020-03-18 バイオマトリカ，インク． 周囲温度における血液サンプル中の変性されていないポリペプチド、核酸、およびエキソソームの安定化
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
CN107257806B (zh) 2014-12-22 2021-08-10 戊瑞治疗有限公司 用于治疗pvns的抗csf1r抗体
LT3283527T (lt) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. Kompleksinė terapija vėžio gydymui
EP3298032A1 (en) * 2015-05-18 2018-03-28 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
MA42843A (fr) 2015-09-16 2018-07-25 Ablexis Llc Anticorps anti-cd115
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
MX2020002301A (es) 2017-09-13 2020-07-13 Five Prime Therapeutics Inc Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
WO2019199476A1 (en) 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
CN119176871A (zh) 2018-07-24 2024-12-24 免疫医疗有限责任公司 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
CN113301960B (zh) * 2018-12-13 2025-06-03 财团法人生物技术开发中心 抗人类csf-1r抗体和其用途
AU2020228367A1 (en) * 2019-02-26 2021-10-14 Vivasor, Inc. Antigen binding proteins that bind BCMA
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
AU2020346886A1 (en) * 2019-09-13 2022-04-14 Memorial Hospital For Cancer And Allied Diseases Anti-CD371 antibodies and uses thereof
US20220370463A1 (en) * 2019-09-19 2022-11-24 New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
EP4034558A1 (en) 2019-09-26 2022-08-03 Roche Diagnostics GmbH Anti-csf-1r antibody
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
WO2021091964A1 (en) 2019-11-04 2021-05-14 Duke University Treatment for primary and metastatic cancer
CN111068054B (zh) * 2019-11-06 2022-02-11 浙江大学医学院附属第一医院 以csf1r作为药物靶点治疗肿瘤的药剂及其制备方法
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
US11419822B2 (en) 2020-12-14 2022-08-23 AmMax Bio, Inc. High concentration formulations of anti-CSF1 and anti-CSF1R antibodies
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CN113712526B (zh) * 2021-09-30 2022-12-30 四川大学 一种脉搏波提取方法、装置、电子设备及存储介质
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024138213A2 (en) * 2022-12-23 2024-06-27 The Wistar Institute Of Anatomy And Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
WO2024238787A1 (en) 2023-05-17 2024-11-21 Syndax Pharmaceuticals, Inc. Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025210175A1 (en) * 2024-04-04 2025-10-09 Centre National De La Recherche Scientifique Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025226754A1 (en) 2024-04-23 2025-10-30 Amgen Inc. Method for predicting osmolality of protein solutions

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0200252B1 (en) * 1985-05-02 1999-03-10 Yamanouchi Europe B.V. Tablets comprising trimethoprim and a sulfonamide
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
KR970002917B1 (ko) 1988-05-27 1997-03-12 씨네겐 인코포레이티드 인터루킨-i 억제제
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
WO1992022646A1 (en) 1991-06-14 1992-12-23 Dnx Corp. Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
DE69334100T2 (de) 1992-11-13 2007-07-19 Immunex Corp., Seattle Elk ligand, ein cytokin
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
CA2189028A1 (en) 1994-04-15 1995-10-26 Gary M. Fox Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
DE69732667T2 (de) 1996-12-12 2006-01-19 Prolume, Ltd., Beverly Hills Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
WO1998028424A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1019082B2 (en) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO1999045009A1 (en) 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ES2262518T5 (es) 1999-06-07 2009-05-08 Immunex Corporation Antagonistas de tek.
WO2001016344A1 (fr) 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
ATE240744T1 (de) 1999-10-28 2003-06-15 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
ATE514676T1 (de) 1999-11-24 2011-07-15 Sugen Inc Ionisierbare indolinon derivate und deren verwendung als ptk liganden
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7074408B2 (en) 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
DE60332483D1 (de) * 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2008288974B2 (en) 2014-08-28
PT2188313T (pt) 2017-12-12
PE20091004A1 (es) 2009-08-19
US9303084B2 (en) 2016-04-05
EP2188313A1 (en) 2010-05-26
EP2188313B1 (en) 2017-11-01
EA023555B1 (ru) 2016-06-30
CN101802008A (zh) 2010-08-11
SG10201500328QA (en) 2015-03-30
CY1119755T1 (el) 2018-06-27
ES2650224T3 (es) 2018-01-17
EA201000357A1 (ru) 2010-12-30
BRPI0815368A2 (pt) 2015-02-10
LT2188313T (lt) 2018-02-26
CN101802008B (zh) 2015-04-01
HRP20171741T1 (hr) 2017-12-29
AR068347A1 (es) 2009-11-11
EP2592093A1 (en) 2013-05-15
JP2015107118A (ja) 2015-06-11
EP3330292A1 (en) 2018-06-06
JP2018007683A (ja) 2018-01-18
KR101770429B1 (ko) 2017-08-22
TWI595005B (zh) 2017-08-11
JP5718640B2 (ja) 2015-05-13
PL2188313T3 (pl) 2018-04-30
CR11282A (es) 2010-06-28
JP6189281B2 (ja) 2017-08-30
US20140105916A1 (en) 2014-04-17
US9988457B2 (en) 2018-06-05
EP2589610A1 (en) 2013-05-08
ZA201001541B (en) 2015-07-29
JP2010536378A (ja) 2010-12-02
US20090155164A1 (en) 2009-06-18
US8513199B2 (en) 2013-08-20
CL2008002444A1 (es) 2009-09-04
WO2009026303A1 (en) 2009-02-26
US8182813B2 (en) 2012-05-22
MX2010001918A (es) 2010-03-11
TW200911829A (en) 2009-03-16
RS56743B1 (sr) 2018-03-30
DK2188313T3 (en) 2017-12-11
NZ583282A (en) 2012-09-28
CA2696761C (en) 2017-02-14
SI2188313T1 (en) 2018-04-30
HUE037265T2 (hu) 2018-08-28
NO2188313T3 (enExample) 2018-03-31
CA2696761A1 (en) 2009-02-26
KR20100056492A (ko) 2010-05-27
US20120230987A1 (en) 2012-09-13
US20160340434A1 (en) 2016-11-24
AU2008288974A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
EA201000357A1 (ru) Антигенсвязывающие белки, связывающие с-fms человека
EA201000490A1 (ru) Антигенсвязывающие белки, связывающиеся с человеческим белком gm-csf
TN2012000167A1 (en) Human il-23 antigen binding proteins
MA34004B1 (fr) Protéines de liaison à cd127
JOP20190017B1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201500204A1 (ru) Антитела к ox40 и способы их применения
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
EA202191658A1 (ru) Антитела против фактора c2b комплемента человека и способы применения
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana